Navigation Links
Syndax Pharmaceuticals Appoints Arlene Morris as CEO
Date:4/18/2012

WALTHAM, Mass., April 18, 2012 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., an oncology company moving into phase 3 having completed randomized, placebo controlled phase 2 studies, announced the appointment of Arlene M. Morris as chief executive officer.  Joanna Horobin, MD will serve as president. 

"Syndax is leading the field of epigenetics—a novel way to control gene regulation—to address unmet needs in cancer due to the problem of resistance," said Dennis Podlesak, chairman of the Syndax board of directors. "With the positive phase 2 randomized, placebo-controlled data and the addition of Arlene Morris to our impressive leadership team, Syndax is well positioned to successfully complete the final phase of clinical development to achieve our goal of providing a new treatment option for women with metastatic breast cancer."

During her eight years as president and CEO at Affymax, Ms. Morris led the company through the development of peginesatide (Omontys®), a strategic collaboration with Takeda and an Initial Public Offering. Prior to Affymax Ms. Morris was the president and CEO of Clearview Projects, an advisory firm which counseled biopharmaceutical and biotechnology companies on strategic transactions. Before that she was the senior vice president, business development at Coulter, a biotechnology company focused on immunotherapeutic approaches to cancer, autoimmune and infectious diseases, where she completed numerous transactions including a $1.0 billion merger between Corixa and Coulter. Ms. Morris began her career at Johnson & Johnson (J&J) as a sales representative rising to vice president of business development. Ms. Morris received her bachelor's degree in biology and chemistry from Carlow College. In addition to Syndax Ms. Morris serves on the board of directors of Neovacs and MediciNova.

"After working with Syndax as a director over the past nine months
'/>"/>

SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer
2. Syndax Pharmaceuticals to Present at Upcoming Fall Conferences
3. Syndax Pharmaceuticals Announces Issuance of EU Patent for Entinostat
4. Syndax Pharmaceuticals to Present at BIO Investor Forum
5. Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
7. Onyx Pharmaceuticals to Present at Upcoming Investor Conferences
8. Avanir Pharmaceuticals to Participate in Citi 2012 Global Health Care Conference
9. Swedish Bactiguard to Enter Into an Exclusive Distribution Agreement With Cadila Pharmaceuticals
10. BioDelivery Sciences Receives Patent Allowance Triggering $15 Million Milestone Payment from Endo Pharmaceuticals
11. Questcor Pharmaceuticals to Present at the Leerink Swann Global Healthcare Conference on February 16, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Involution Studios , a ... a new infographic, Understanding Ebola . The ... designed, easy to follow informative tool for anyone wanting ... symptoms and prevention. , "As the news has spread ... Ebola outbreak represents not only a healthcare crisis with ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Grace Century, ... and healthcare projects, announces the addition of Dr. ... to its advisory team. Dr. Siddiqui will provide further ... , A graduate of University College Medical School ... degreed in medicine in 2001. With further certification as ...
(Date:10/22/2014)... --  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... and diseases, announced today that the U.S. Patent and ... a composition of matter patent application that covers the ... This is Synthetic Biologics, first allowed patent application directly ... the Company,s extensive C. difficile patent estate. ...
(Date:10/22/2014)... -- Research and Markets  has announced the addition ... Application, Geography - Global Analysis and Forecast (2014 - ... Organic electronics, also called as polymer electronics or plastic ... with small conductive molecules and electrically conductive polymers. It ... are carbon based, made using synthetic strategies developed in ...
Breaking Biology Technology:Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3
... May 24, 2010 Simbionix USA Corporation,the world,s leading provider of ... is launching,two new hands-on training systems- the Lap Nepherctomy simulation module and,the ... AUA annual meeting in San Francisco next week. , ... The Lap ...
... BEIJING , May 24 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: ... Weidong Yin ,Chairman, President & CEO, will present at the 2010 UBS Global ... London,England . Sinovac,s presentation is scheduled for Wednesday, June 2, 2010 ... , , ...
... ... ... plans to add to its natural color capabilities by investing $16 million at its Color ... facility dedicated wholly to natural colors production. The plant will be the largest and most ...
Cached Biology Technology:Simbionix to Reveal Two new Products at the Upcoming American Urology Association (AUA) Annual Meeting 2Simbionix to Reveal Two new Products at the Upcoming American Urology Association (AUA) Annual Meeting 3Sinovac to Present at 2010 UBS Global Specialty Pharmaceuticals Conference 2Sensient Technologies Corporation Announces Major Investment in Natural Colors 2
(Date:10/25/2014)... 2014 Research and Markets  has announced ... 2014-2018" report to their offering. ... on the basis of their physical or behavioral patterns. ... traits such as fingerprints, face recognition, DNA, palm print, ... as keystroke patterns and speech pattern/voice recognition. ...
(Date:10/22/2014)... The Nano-Bio Manufacturing Consortium (NBMC), an industry-academia ... (AFRL), has chosen a project proposed by the Arizona ... Arizona College of Medicine – Tucson ... is to assess different sweat collection methods and devices ... under a variety of human-body conditions, the results of ...
(Date:10/22/2014)... 21, 2014 Aware, Inc. (NASDAQ: AWRE ... reported financial results for its third quarter ended September 30, ... was $6.0 million, an increase of 40% compared to $4.3 ... the third quarter of 2014 was $4.1 million compared to ... income in the current three month period was primarily due ...
Breaking Biology News(10 mins):Biometrics Market in Europe 2014-2018: Key Vendors are 3M Cogent, Cognitec, NEC and Safran 2Biometrics Market in Europe 2014-2018: Key Vendors are 3M Cogent, Cognitec, NEC and Safran 3Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 2Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 3Aware, Inc. Reports Third Quarter 2014 Financial Results 2Aware, Inc. Reports Third Quarter 2014 Financial Results 3Aware, Inc. Reports Third Quarter 2014 Financial Results 4Aware, Inc. Reports Third Quarter 2014 Financial Results 5Aware, Inc. Reports Third Quarter 2014 Financial Results 6Aware, Inc. Reports Third Quarter 2014 Financial Results 7
... hold great promise for benefiting degenerative diseases, and do ... grown in a manner compatible with clinical use (i.e., ... for immunosuppression. These were a few of a number ... by Evan Y. Snyder, M.D., Ph.D., and spearheaded by ...
... from another may depend on the number of receptors ... of receptors is controlled by levels of a ubiquitous ... found. , Everything from the ability to concentrate, perceive ... sclerosis, muscular dystrophy, post-traumatic stress syndrome and schizophrenia is ...
... launch of the first large-scale study to evaluate a ... today by study collaborators in the United States and ... participants at five sites throughout South Africa and is ... are part of the HIV Vaccine Trials Network (HVTN), ...
Cached Biology News:Stem cells act through multiple mechanisms to benefit mice with neurodegenerative disease 2Stem cells act through multiple mechanisms to benefit mice with neurodegenerative disease 3Stem cells act through multiple mechanisms to benefit mice with neurodegenerative disease 4Stem cells act through multiple mechanisms to benefit mice with neurodegenerative disease 5Bisexual fruit flies show new role for neurochemical 2Africa's first large-scale HIV vaccine study launches 2Africa's first large-scale HIV vaccine study launches 3Africa's first large-scale HIV vaccine study launches 4
HybriWell™ hybridization sealing system, 20 mm diameter chamber, 0.15 mm deep *set of 100*...
Recombinant Feline IL-5...
... Checker Kits provide two highly efficient methods ... time-consuming plasmid preparation. By using the large-scale ... need to do is to transfer partial ... the transformation plates into the solutions provided ...
Recombinant Equine IL-4, CF...
Biology Products: